The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).
Anas Younes
Employment or Leadership Position - Memorial Sloan-Kettering Cancer Center
Honoraria - Bayer; Bristol-Myers Squibb; Celgene; Incyte; Janssen Research & Development; Millennium; Sanofi ; Seattle Genetics
Research Funding - Curis; Johnson & Johnson; Novartis
Pier Luigi Zinzani
No relevant relationships to disclose
Laurie Helen Sehn
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Peter W. M. Johnson
Consultant or Advisory Role - Johnson & Johnson
Honoraria - Johnson & Johnson
Research Funding - Janssen-Cilag
Randy D. Gascoyne
Consultant or Advisory Role - Celgene; Infinity Pharmaceuticals; Janssen; Seattle Genetics
Honoraria - Seattle Genetics
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Kevin M. Bellew
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen Pharmaceutical
Research Funding - Janssen Research & Development
Jessica Vermeulen
Employment or Leadership Position - Janssen
Stock Ownership - Janssen
Sen Hong Zhuang
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Steven Sun
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Louis M. Staudt
No relevant relationships to disclose
Wyndham Hopkins Wilson
No relevant relationships to disclose